Abstract
Oncogenic ROS1 mutations are found to occur in 1-2% of NSCLCs, and efficacy of single-agent Crizotinib (a ROS1 tyrosine-kinase inhibitor) has been demonstrated in ROS1-positive NSCLC. However, our knowledge on the natural disease course in ROS1-positive compared to ROS1-wild type (WT) NSCLC is currently limited. Furthermore, since no randomized prospective trials are likely to be planned to assess treatment outcomes in ROS-1 positive patients, the question whether ROS1-positivity is a favorable or an unfavorable prognostic factor in advanced NSCLC, may remain unanswered. To address this important question, we undertook a systematic review of published literature on the natural history of ROS1-positive NSCLC.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
